Cargando…
Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?
BACKGROUND: Childhood-onset systemic lupus erythematosus (cSLE) is an incurable multi-systemic autoimmune disease. Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. The objective of this study was to assess the prevalence of the IFN-I signature and the contribution of cytoso...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763828/ https://www.ncbi.nlm.nih.gov/pubmed/29321042 http://dx.doi.org/10.1186/s13075-017-1501-z |
_version_ | 1783291961185140736 |
---|---|
author | Wahadat, M. Javad Bodewes, Iris L. A. Maria, Naomi I. van Helden-Meeuwsen, Cornelia G. van Dijk-Hummelman, Annette Steenwijk, Eline C. Kamphuis, Sylvia Versnel, Marjan A. |
author_facet | Wahadat, M. Javad Bodewes, Iris L. A. Maria, Naomi I. van Helden-Meeuwsen, Cornelia G. van Dijk-Hummelman, Annette Steenwijk, Eline C. Kamphuis, Sylvia Versnel, Marjan A. |
author_sort | Wahadat, M. Javad |
collection | PubMed |
description | BACKGROUND: Childhood-onset systemic lupus erythematosus (cSLE) is an incurable multi-systemic autoimmune disease. Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. The objective of this study was to assess the prevalence of the IFN-I signature and the contribution of cytosolic nucleic acid receptors to IFN-I activation in a cohort of primarily white cSLE patients. METHODS: The IFN-I score (positive or negative), as a measure of IFN-I activation, was assessed using real-time quantitative PCR (RT-PCR) expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs). Innate immune receptor expression was determined by RT-PCR and flow cytometry. To clarify the contribution of RNA-binding RIG-like receptors (RLRs) and DNA-binding receptors (DBRs) to IFN-I activation, peripheral blood mononuclear cells (PBMCs) from patients were treated with BX795, a TANK-binding kinase 1 (TBK1) inhibitor blocking RLR and DBR pathways. RESULTS: The IFN-I signature was positive in 57% of cSLE patients and 15% of the HCs. Upregulated gene expression of TLR7, RLRs (IFIH1, DDX58, DDX60, DHX58) and DBRs (ZBP-1, IFI16) was observed in CD14+ monocytes of the IFN-I-positive cSLE patients. Additionally, RIG-I and ZBP-1 protein expression was upregulated in these cells. Spontaneous IFN-I stimulated gene (ISG) expression in PBMCs from cSLE patients was inhibited by a TBK1-blocker. CONCLUSIONS: IFN-I activation, assessed as ISG expression, in cSLE is associated with increased expression of TLR7, and RNA and DNA binding receptors, and these receptors contribute to IFN-I activation via TBK1 signaling. TBK1-blockers may therefore be a promising treatment target for SLE. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-017-1501-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5763828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57638282018-01-17 Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? Wahadat, M. Javad Bodewes, Iris L. A. Maria, Naomi I. van Helden-Meeuwsen, Cornelia G. van Dijk-Hummelman, Annette Steenwijk, Eline C. Kamphuis, Sylvia Versnel, Marjan A. Arthritis Res Ther Research Article BACKGROUND: Childhood-onset systemic lupus erythematosus (cSLE) is an incurable multi-systemic autoimmune disease. Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. The objective of this study was to assess the prevalence of the IFN-I signature and the contribution of cytosolic nucleic acid receptors to IFN-I activation in a cohort of primarily white cSLE patients. METHODS: The IFN-I score (positive or negative), as a measure of IFN-I activation, was assessed using real-time quantitative PCR (RT-PCR) expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs). Innate immune receptor expression was determined by RT-PCR and flow cytometry. To clarify the contribution of RNA-binding RIG-like receptors (RLRs) and DNA-binding receptors (DBRs) to IFN-I activation, peripheral blood mononuclear cells (PBMCs) from patients were treated with BX795, a TANK-binding kinase 1 (TBK1) inhibitor blocking RLR and DBR pathways. RESULTS: The IFN-I signature was positive in 57% of cSLE patients and 15% of the HCs. Upregulated gene expression of TLR7, RLRs (IFIH1, DDX58, DDX60, DHX58) and DBRs (ZBP-1, IFI16) was observed in CD14+ monocytes of the IFN-I-positive cSLE patients. Additionally, RIG-I and ZBP-1 protein expression was upregulated in these cells. Spontaneous IFN-I stimulated gene (ISG) expression in PBMCs from cSLE patients was inhibited by a TBK1-blocker. CONCLUSIONS: IFN-I activation, assessed as ISG expression, in cSLE is associated with increased expression of TLR7, and RNA and DNA binding receptors, and these receptors contribute to IFN-I activation via TBK1 signaling. TBK1-blockers may therefore be a promising treatment target for SLE. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-017-1501-z) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-10 2018 /pmc/articles/PMC5763828/ /pubmed/29321042 http://dx.doi.org/10.1186/s13075-017-1501-z Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wahadat, M. Javad Bodewes, Iris L. A. Maria, Naomi I. van Helden-Meeuwsen, Cornelia G. van Dijk-Hummelman, Annette Steenwijk, Eline C. Kamphuis, Sylvia Versnel, Marjan A. Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
title | Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
title_full | Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
title_fullStr | Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
title_full_unstemmed | Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
title_short | Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? |
title_sort | type i ifn signature in childhood-onset systemic lupus erythematosus: a conspiracy of dna- and rna-sensing receptors? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763828/ https://www.ncbi.nlm.nih.gov/pubmed/29321042 http://dx.doi.org/10.1186/s13075-017-1501-z |
work_keys_str_mv | AT wahadatmjavad typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT bodewesirisla typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT marianaomii typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT vanheldenmeeuwsencorneliag typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT vandijkhummelmanannette typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT steenwijkelinec typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT kamphuissylvia typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors AT versnelmarjana typeiifnsignatureinchildhoodonsetsystemiclupuserythematosusaconspiracyofdnaandrnasensingreceptors |